Caribou Biosciences, Inc. (CRBU)
| Market Cap | 181.68M +73.0% |
| Revenue (ttm) | 11.16M +11.7% |
| Net Income | -148.13M |
| EPS | -1.59 |
| Shares Out | 96.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 760,646 |
| Open | 1.920 |
| Previous Close | 1.890 |
| Day's Range | 1.840 - 1.930 |
| 52-Week Range | 0.660 - 3.535 |
| Beta | 2.55 |
| Analysts | Strong Buy |
| Price Target | 10.75 (+471.81%) |
| Earnings Date | Mar 5, 2026 |
About CRBU
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCM... [Read more]
Financial Performance
In 2025, Caribou Biosciences's revenue was $11.16 million, an increase of 11.66% compared to the previous year's $9.99 million. Losses were -$148.13 million, -0.66% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CRBU stock is "Strong Buy." The 12-month stock price target is $10.75, which is an increase of 471.81% from the latest price.
News
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial result...
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample
BOULDER, Colo.--(BUSINESS WIRE)-- #NGS--Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosc...
Caribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will ...
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data d...
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
BERKELEY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hos...
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
Vispa-cel (CB-010) ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for outpatient use, highlighting its potential as a best-in-class...
Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>
Caribou Biosciences Inc. (NASDAQ:CRBU) stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced its first clinic...
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with longer-ter...
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma
BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hol...
Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
BERKELEY, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,...
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $184 million in cash, cash equivalents, and marketable securities expected to fund the Company's curre...
Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference
BERKELEY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, ...
Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update
-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company's cur...
Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference
BERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, ...
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
-- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company's cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / April 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company")...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") ...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") ...
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") ...
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Investors to Connect
NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company")...
Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company")...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company")...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company")...